Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Research output: Contribution to journalArticlepeer-review


  • Tom Waddell
  • Ian Chau
  • David Cunningham
  • David Gonzalez
  • Alicia Frances Clare Okines
  • Alicia Frances
  • Clare Okines
  • Andrew Wotherspoon
  • Claire Saffery
  • Jonathan Wadsley
  • Wasat Mansoor
  • Tom Crosby
  • Fareeda Coxon
  • David Smith
  • Justin Waters
  • Timothy Iveson
  • Stephen Falk
  • Sarah Slater
  • Clare Peckitt
  • Yolanda Barbachano

Colleges, School and Institutes


EGFR overexpression occurs in 27-55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in patients with advanced oesophagogastric adenocarcinoma.

Bibliographic note

Copyright © 2013 Elsevier Ltd. All rights reserved.


Original languageEnglish
Pages (from-to)481-9
Number of pages9
JournalThe Lancet Oncology
Issue number6
Publication statusPublished - May 2013


  • Adenocarcinoma, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Chi-Square Distribution, Deoxycytidine, Disease-Free Survival, Early Termination of Clinical Trials, Epirubicin, Esophageal Neoplasms, Female, Fluorouracil, Great Britain, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Molecular Targeted Therapy, Multivariate Analysis, Odds Ratio, Organoplatinum Compounds, Proportional Hazards Models, Protein Kinase Inhibitors, Receptor, Epidermal Growth Factor, Stomach Neoplasms, Time Factors, Treatment Outcome, Tumor Markers, Biological